AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED)

NCT00122343 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Endometrial Cancer

Interventions

DRUG: ridaforolimus

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]